AI Engines For more Details: Perplexity Kagi Labs You
GABA-A Receptor Modulation: Tracazolate hydrochloride acts as a positive allosteric modulator of the GABA-A receptor. GABA-A receptors are ion channels that mediate inhibitory neurotransmission in the central nervous system. Modulation of these receptors can affect neuronal excitability and synaptic transmission.
Anxiolytic Effects: GABA-A receptor positive allosteric modulators like tracazolate hydrochloride have been investigated for their potential anxiolytic (anti-anxiety) effects. By enhancing the activity of GABA-A receptors, tracazolate hydrochloride may increase the inhibitory tone in the brain, leading to reduced anxiety and relaxation.
Anticonvulsant Effects: Modulation of GABA-A receptors can also influence seizure activity in the brain. Some positive allosteric modulators of GABA-A receptors have demonstrated anticonvulsant properties in preclinical studies. Tracazolate hydrochloride may have potential as an anticonvulsant medication, although further research is needed to evaluate its efficacy and safety for this indication.
Memory Enhancement: GABA-A receptor modulation has been linked to cognitive function and memory processes. Some positive allosteric modulators of GABA-A receptors have shown memory-enhancing effects in animal models. Tracazolate hydrochloride may have potential as a cognitive enhancer, although its effects on memory and learning would require further investigation.
Potential Therapeutic Applications: While tracazolate hydrochloride has been primarily studied in preclinical research, its clinical development and therapeutic applications have been limited. More research would be needed to evaluate its efficacy, safety, and potential medical uses in humans. Additionally, the precise mechanisms of action and pharmacological effects of tracazolate hydrochloride require further elucidation.
Side Effects: As with any pharmacological agent, tracazolate hydrochloride may have potential side effects. These could include sedation, dizziness, cognitive impairment, or other central nervous system effects. The safety profile of tracazolate hydrochloride would need to be thoroughly evaluated in clinical trials before it could be considered for medical use.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
ADHD | 1.6 | 0.2 | 7 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
Allergic Rhinitis (Hay Fever) | 0.8 | 0.8 | |
Allergies | 1.4 | 1 | 0.4 |
Allergy to milk products | 0.9 | 0.5 | 0.8 |
Alopecia (Hair Loss) | 1.3 | 1.3 | |
Alzheimer's disease | 1.4 | 4.4 | -2.14 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.6 | -0.2 |
Ankylosing spondylitis | 1.9 | 0.5 | 2.8 |
Anorexia Nervosa | 0.4 | 2 | -4 |
Antiphospholipid syndrome (APS) | 1.4 | 0.1 | 13 |
Asthma | 0.4 | 0.5 | -0.25 |
Atherosclerosis | 0.4 | 1.6 | -3 |
Atrial fibrillation | 2 | 0.7 | 1.86 |
Autism | 4.4 | 4.1 | 0.07 |
Barrett esophagus cancer | 0.2 | -0.2 | |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 1.1 | 1 | 0.1 |
Brain Trauma | 0.5 | -0.5 | |
Carcinoma | 1.8 | 1.3 | 0.38 |
Celiac Disease | 1 | 1.5 | -0.5 |
Cerebral Palsy | 0.4 | 1.4 | -2.5 |
Chronic Fatigue Syndrome | 1.6 | 3.6 | -1.25 |
Chronic Kidney Disease | 1.6 | 1.4 | 0.14 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.6 | 0 |
Chronic Urticaria (Hives) | 0.8 | 0.2 | 3 |
Coagulation / Micro clot triggering bacteria | 0.9 | 1.5 | -0.67 |
Colorectal Cancer | 1.9 | 0.4 | 3.75 |
Constipation | 0.7 | 0.9 | -0.29 |
Coronary artery disease | 0.8 | 0.6 | 0.33 |
COVID-19 | 3.9 | 6.1 | -0.56 |
Crohn's Disease | 2.9 | 3 | -0.03 |
cystic fibrosis | 0.3 | 0.5 | -0.67 |
deep vein thrombosis | 0.3 | 1 | -2.33 |
Depression | 4.3 | 4.5 | -0.05 |
Dermatomyositis | 0.2 | 0.2 | |
Eczema | 0.1 | 0.7 | -6 |
Endometriosis | 1.6 | 0.4 | 3 |
Epilepsy | 1 | 1.6 | -0.6 |
Fibromyalgia | 2.3 | 0.5 | 3.6 |
Functional constipation / chronic idiopathic constipation | 3.1 | 2.1 | 0.48 |
gallstone disease (gsd) | 1.6 | 0.5 | 2.2 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 1.1 | -0.57 |
Generalized anxiety disorder | 0.8 | 0.4 | 1 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.2 | -0.2 | |
Gout | 0.1 | -0.1 | |
Graves' disease | 0.5 | 0.9 | -0.8 |
Halitosis | 0.1 | 0.2 | -1 |
Hashimoto's thyroiditis | 2 | 0.2 | 9 |
Hidradenitis Suppurativa | 0.3 | 0.3 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.4 | 1.3 | 0.08 |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
hyperglycemia | 0.1 | 0.9 | -8 |
hypersomnia | 0.6 | -0.6 | |
hypertension (High Blood Pressure | 1.2 | 1.6 | -0.33 |
Hypothyroidism | 0.6 | -0.6 | |
Hypoxia | 0.5 | 0.5 | |
IgA nephropathy (IgAN) | 0.4 | -0.4 | |
Inflammatory Bowel Disease | 0.9 | 5.7 | -5.33 |
Insomnia | 0.7 | 0.6 | 0.17 |
Intelligence | 0.4 | 0.4 | |
Intracranial aneurysms | 1.3 | 1.3 | |
Irritable Bowel Syndrome | 1.6 | 1.4 | 0.14 |
Liver Cirrhosis | 2.6 | 1.6 | 0.63 |
Long COVID | 2.8 | 4.2 | -0.5 |
Low bone mineral density | 0.6 | -0.6 | |
Lung Cancer | 0.1 | 0.8 | -7 |
ME/CFS with IBS | 0.8 | 1.2 | -0.5 |
ME/CFS without IBS | 0.7 | 0.9 | -0.29 |
Metabolic Syndrome | 3.1 | 3.1 | 0 |
Mood Disorders | 5.5 | 4.6 | 0.2 |
multiple chemical sensitivity [MCS] | 0.2 | 0.4 | -1 |
Multiple Sclerosis | 2.1 | 4.2 | -1 |
Multiple system atrophy (MSA) | 0.4 | 0.8 | -1 |
Neuropathy (all types) | 0.6 | 0.1 | 5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 2.7 | -1.7 |
Obesity | 3.6 | 1.4 | 1.57 |
obsessive-compulsive disorder | 3.4 | 2 | 0.7 |
Osteoarthritis | 0.6 | 0.4 | 0.5 |
Osteoporosis | 0.9 | 0.5 | 0.8 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 1.1 | 3.3 | -2 |
Polycystic ovary syndrome | 2.1 | 1.5 | 0.4 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.1 | 1 |
Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
Psoriasis | 1.7 | 1.9 | -0.12 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.4 | 1.1 | 1.18 |
Rosacea | 1.4 | 0.7 | 1 |
Schizophrenia | 1.9 | 1.6 | 0.19 |
scoliosis | 0.1 | 0.6 | -5 |
Sjögren syndrome | 1.2 | 1.3 | -0.08 |
Sleep Apnea | 0.9 | 1.1 | -0.22 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
Stress / posttraumatic stress disorder | 1.4 | 0.8 | 0.75 |
Systemic Lupus Erythematosus | 1.7 | 1.3 | 0.31 |
Tic Disorder | 0.9 | 0.9 | |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 2 | 1.4 | 0.43 |
Type 2 Diabetes | 3.3 | 3.3 | 0 |
Ulcerative colitis | 1.3 | 1.9 | -0.46 |
Unhealthy Ageing | 2.6 | 1.3 | 1 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.